NAMSA has expanded its microbiology laboratory in Irvine, CA to employ the latest technology for microbiology and sterility assurance testing. Set to open in spring 2013, the new lab space will be used for in vitro toxicology, sterility, and bioburden testing, NAMSA reported in a press release.
Increasing capacity by nearly 50%, the expansion will not affect current services, NAMSA reported.
med fusion and Theranostics Health have entered into a Market Development Agreement to validate the clinical utility of Theranostics' TheraLink Assays for use in patients with malignant diseases. The goal of this relationship is to help accelerate advancement of new methods in molecular diagnostics testing and their use in personalized predictive treatments.
IPS Testing, the Appleton-based independent testing laboratory, has just announced that it has received ISO 17025 accreditation. This is the quality standard recognized globally for testing and calibration laboratories.
With this certification, IPS Testing is now accredited for ICP analysis of heavy metals and GC-MS analysis of phthalates. The company has also added toy testing to its menu of services.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo.
Today at the European Stroke Conference in Lisbon, Portugal, Stryker announced the results of the TREVO 2 clinical trial. The study met the primary effectiveness endpoint, with the Trevo Retriever achieving significantly better post-device revascularization than the Merci Retriever (86.4% in the Trevo Retriever arm compared to 60% in the Merci Retriever arm). The rates of functional independence at 90 days for patients treated with the Trevo Retriever were also better than for the Merci Retriever (40% mRS less than or equal to 2 compared to 21.8%).
The company has launched a second Phase I clinical trial of a vaccine designed to prevent a bird-flu pandemic.
Novavax, Inc. announced today that it has begun enrollment in a second Phase I clinical trial of its monovalent virus-like particle (VLP) vaccine candidate to prevent potential pandemic disease due to A/H5N1 avian influenza viruses ("bird flu"). This randomized, observer-blind, dose-ranging, placebo-controlled trial is being conducted under the company's contract with the U.S.